Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Bisphosphonate Therapy in MONA Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02823925
Recruitment Status : Completed
First Posted : July 6, 2016
Last Update Posted : July 6, 2016
Information provided by (Responsible Party):
Karin Pichler, Medical University Innsbruck

Brief Summary:
Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder is a rare inherited progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (MMP2) gene. Treatment options are limited. The investigators reviewed the outcome of patients affected with MONA and treated with intravenous bisphosphonates in the clinical Center.

Condition or disease Intervention/treatment
Bone Density Pain Fracture Drug: Pamidronate or Zoledronate

Detailed Description:

Assessment of the patients:

After informed consent had been obtained from the patients affected from MONA spectrum disorder the investigators assessed the patients regarding the following characteristics: consanguinity, clinical symptoms at diseases on-set, age at on-set of symptoms and age at diagnosis, cognitive development, progression of clinical symptoms related to the diagnosis, molecular investigations, associated disorders as well as therapies besides bisphosphonate therapy. Informed consent from the patients was also obtained to publish the patient's photographs. All investigations are performed according to the relevant ethical guidelines.

Bisphosphonate therapy:

The reported patients received intravenous bisphosphonate therapy either with pamidronate (1 mg/kg/d on two consecutive days every 3 months) or zoledronate (a single dose of 0.05 mg/kg/day every 6 month).

Evaluation of disease progression and therapeutic success:

To assess both progression of MONA spectrum disorder and therapeutic success the patients were regularly evaluated clinically in 3 to 6 month intervals. Clinical evaluation comprised an internal, neurological and orthopaedic status as well as a general assessment of neurocognitive function. Additionally, need for oral analgesic therapy was documented. In irregular intervals, depending also on the clinical symptoms, x-rays of hand and feet were taken and a densitometry of the total body, lumbar spine and hip was performed.

Layout table for study information
Study Type : Observational
Actual Enrollment : 3 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Bisphosphonates in Multicentric Osteolysis, Nodulosis and Arthropathy (MONA) Spectrum Disorder - an Alternative Therapeutic Approach
Study Start Date : February 2013
Actual Primary Completion Date : January 2015

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. bone mineral density [ Time Frame: 10 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Three siblings were enrolled in the study.

Inclusion Criteria:

  • genetically confirmed MONA spectrum disorder
  • treatment with bisphosphonates intravenously
  • positive informed consent

Exclusion Criteria:

  • genetically confirmed MONA spectrum disorder treated otherwise than with bisphosphonates
  • oral treatment with bisphosphonates in MONA spectrum disorder
  • other inherited osteolysis syndromes than MONA spectrum disorder
Layout table for additonal information
Responsible Party: Karin Pichler, MD PhD, Medical University Innsbruck Identifier: NCT02823925    
Other Study ID Numbers: SREP-16-11962A
First Posted: July 6, 2016    Key Record Dates
Last Update Posted: July 6, 2016
Last Verified: July 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Zoledronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs